African Sleeping Sickness (Trypanosoma brucei)
Overview
Plain-Language Overview
African Sleeping Sickness (Trypanosoma brucei) is a disease caused by a parasite transmitted through the bite of an infected tsetse fly. It primarily affects the nervous system, leading to symptoms that worsen over time. Early signs include fever, headaches, and joint pain, but as the disease progresses, it causes sleep disturbances, confusion, and difficulty with coordination. The infection can severely disrupt normal brain function, which is why it is called sleeping sickness. Without treatment, the disease can be fatal due to damage to the brain and other organs. The condition is most common in rural areas of sub-Saharan Africa where the tsetse fly lives.
Clinical Definition
African Sleeping Sickness (Trypanosoma brucei) is a parasitic infection caused by the protozoan Trypanosoma brucei, transmitted by the bite of the tsetse fly. The disease progresses through two stages: an initial hemolymphatic phase characterized by fever, lymphadenopathy, and systemic symptoms, followed by a meningoencephalitic phase where the parasite invades the central nervous system (CNS). This CNS involvement leads to neuropsychiatric symptoms such as sleep cycle disruption, behavioral changes, and neurological deficits. The pathogenesis involves parasite evasion of the immune system through antigenic variation of the variant surface glycoprotein (VSG). The disease is endemic in sub-Saharan Africa and is a major cause of morbidity and mortality if untreated. Diagnosis and management are critical to prevent irreversible CNS damage and death.
Inciting Event
Bite of an infected tsetse fly introduces metacyclic trypomastigotes into the skin.
Injection of parasites during blood meal initiates systemic infection.
Parasite entry into lymphatics leads to early dissemination and lymphadenopathy.
Latency Period
Initial symptoms typically develop within 1 to 3 weeks after the tsetse fly bite.
Early hemolymphatic stage symptoms may appear days to weeks post-infection.
CNS involvement usually occurs weeks to months after initial infection.
Diagnostic Delay
Early symptoms are nonspecific and mimic common febrile illnesses, leading to misdiagnosis.
Limited access to specialized diagnostic tests such as blood smear or CSF analysis delays confirmation.
Lack of awareness in non-endemic areas causes missed diagnosis in travelers.
CNS symptoms may be attributed to other neurological diseases before considering African sleeping sickness.
Clinical Presentation
Signs & Symptoms
Intermittent fever and generalized malaise are early systemic symptoms.
Lymphadenopathy especially in the posterior cervical region is a common early sign.
Headache, pruritus, and joint pains frequently occur during the hemolymphatic phase.
Neuropsychiatric symptoms including confusion, personality changes, and sleep disturbances mark CNS involvement.
Progressive somnolence and movement disorders develop in the meningoencephalitic phase.
History of Present Illness
Initial presentation includes intermittent fevers, headaches, and malaise during the hemolymphatic stage.
Winterbottom sign (posterior cervical lymphadenopathy) is a characteristic early finding.
Progression to the meningoencephalitic stage causes sleep disturbances, behavioral changes, and neurological deficits.
Patients may report daytime somnolence and nighttime insomnia, reflecting CNS involvement.
Late-stage disease includes seizures, coma, and death if untreated.
Past Medical History
Previous exposure to tsetse fly bites or residence in endemic areas increases suspicion.
History of untreated or partially treated trypanosomiasis may lead to relapse or chronic symptoms.
No specific prior medical conditions are required but immunocompromised states may worsen outcomes.
Family History
There is no hereditary predisposition or familial syndrome associated with African sleeping sickness.
Family members living in the same endemic area share similar environmental exposure risks.
No known genetic mutations influence susceptibility or disease severity.
Physical Exam Findings
Winterbottom sign characterized by posterior cervical lymphadenopathy is a classic finding in early-stage African sleeping sickness.
Fever with intermittent spikes is commonly observed during the hemolymphatic phase.
Chancre at the site of tsetse fly bite may be present as a painful, erythematous skin lesion.
Neurological signs such as altered mental status, somnolence, and ataxia appear in the late meningoencephalitic stage.
Tremors and abnormal sleep-wake cycles are hallmark findings in advanced disease.
Diagnostic Workup
Diagnostic Criteria
Diagnosis of African sleeping sickness is established by identifying trypomastigotes in blood, lymph node aspirate, or cerebrospinal fluid (CSF) using microscopy. The presence of parasites in the CSF confirms CNS involvement and the meningoencephalitic stage. Additional diagnostic tools include serologic tests and molecular assays such as PCR to detect Trypanosoma brucei DNA. Clinical suspicion is raised by characteristic symptoms and epidemiologic exposure in endemic areas. Lumbar puncture is essential to stage the disease and guide treatment.
Pathophysiology
Key Mechanisms
Trypanosoma brucei parasites evade immune clearance via antigenic variation of their variant surface glycoprotein (VSG) coat.
Parasite replication in the bloodstream and lymphatics causes systemic inflammation and tissue damage.
CNS invasion leads to meningoencephalitis with disruption of the blood-brain barrier and neuroinflammation.
Host immune response triggers cyclic fevers and lymphadenopathy due to waves of parasitemia.
Hemolymphatic spread results in widespread organ involvement including spleen and liver enlargement.
| Involvement | Details |
|---|---|
| Organs | Lymph nodes become enlarged due to immune activation and parasite infiltration during early infection. |
Brain involvement in late-stage disease leads to characteristic neurological signs including sleep disturbances and cognitive decline. | |
Spleen is involved in immune response and clearance of infected erythrocytes and parasites. | |
| Tissues | Blood is the primary tissue where trypanosomes circulate and cause hemolymphatic symptoms. |
Central nervous system tissue is invaded in late-stage disease causing meningoencephalitis and neurological symptoms. | |
| Cells | Trypanosomes are extracellular protozoan parasites responsible for infection and immune evasion. |
Macrophages phagocytose trypanosomes and present antigens but are evaded by parasite antigenic variation. | |
T lymphocytes mediate adaptive immune responses but are often ineffective due to parasite surface glycoprotein switching. | |
| Chemical Mediators | Tumor necrosis factor-alpha (TNF-α) contributes to systemic inflammation and fever in African sleeping sickness. |
Interferon-gamma (IFN-γ) activates macrophages to kill parasites but also promotes CNS inflammation in late-stage disease. | |
Nitric oxide (NO) produced by activated macrophages has trypanocidal effects but may contribute to tissue damage. |
Treatments
Pharmacological Treatments
Suramin
- Mechanism:
Inhibits enzymes involved in parasite energy metabolism, effective against early-stage Trypanosoma brucei rhodesiense infection.
- Side effects:
Hypersensitivity reactions
Nephrotoxicity
Peripheral neuropathy
- Clinical role:
First-line for early-stage rhodesiense
Pentamidine
- Mechanism:
Interferes with DNA, RNA, and protein synthesis in Trypanosoma brucei gambiense.
- Side effects:
Hypotension
Nephrotoxicity
Pancreatitis
- Clinical role:
First-line for early-stage gambiense
Melarsoprol
- Mechanism:
Arsenic-based compound that inhibits parasite enzymes, crosses blood-brain barrier to treat late-stage CNS infection.
- Side effects:
Encephalopathy
Peripheral neuropathy
Reactive encephalopathy
- Clinical role:
First-line for late-stage CNS involvement
Eflornithine
- Mechanism:
Irreversibly inhibits ornithine decarboxylase, blocking polyamine synthesis essential for parasite growth.
- Side effects:
Bone marrow suppression
Seizures
Gastrointestinal upset
- Clinical role:
First-line for late-stage gambiense
Non-pharmacological Treatments
Supportive care including management of fever, hydration, and nutritional support is essential during treatment.
Vector control measures such as insecticide-treated nets and clearing of tsetse fly habitats reduce transmission risk.
Prevention
Pharmacological Prevention
No widely available chemoprophylaxis exists for African sleeping sickness.
Vector control insecticides may be used to reduce tsetse fly populations but are not pharmacological.
Non-pharmacological Prevention
Avoidance of tsetse fly habitats such as dense vegetation reduces exposure risk.
Use of protective clothing and insect repellents helps prevent bites.
Screening and treatment of infected individuals reduces transmission.
Tsetse fly traps and environmental management are key vector control strategies.
Outcome & Complications
Complications
Severe meningoencephalitis leading to coma and death if untreated.
Cardiac involvement including myocarditis and arrhythmias may occur.
Secondary infections due to immunosuppression increase morbidity.
Seizures and neurological deficits can result from CNS invasion.
| Short-term Sequelae | Long-term Sequelae |
|---|---|
|
|
Differential Diagnoses
African Sleeping Sickness (Trypanosoma brucei) versus Malaria
African Sleeping Sickness (Trypanosoma brucei) | Malaria |
|---|---|
Exposure to tsetse fly habitat in sub-Saharan Africa | Recent travel to or residence in malaria-endemic regions with Anopheles mosquito exposure |
Trypomastigotes of Trypanosoma brucei seen on blood smear | Infection with Plasmodium species detected on blood smear |
Progressive neurological symptoms with daytime somnolence and nighttime insomnia | Paroxysmal fevers with chills and rigors recurring every 48-72 hours |
Identification of Trypanosoma brucei in blood or cerebrospinal fluid | Positive rapid diagnostic test or thick/thin blood smear for Plasmodium |
African Sleeping Sickness (Trypanosoma brucei) versus Neurosyphilis
African Sleeping Sickness (Trypanosoma brucei) | Neurosyphilis |
|---|---|
Subacute progression with early systemic symptoms and rapid CNS involvement | Chronic progressive neurological decline over months to years |
Detection of Trypanosoma brucei in CSF by microscopy or PCR | Positive CSF VDRL or FTA-ABS test |
CSF pleocytosis with presence of trypomastigotes | CSF pleocytosis with lymphocytic predominance and elevated protein without parasites |
African Sleeping Sickness (Trypanosoma brucei) versus Viral Encephalitis (e.g., Herpes Simplex Virus)
African Sleeping Sickness (Trypanosoma brucei) | Viral Encephalitis (e.g., Herpes Simplex Virus) |
|---|---|
Subacute onset with systemic symptoms followed by sleep disturbances | Acute onset of fever, headache, and altered mental status over days |
Identification of Trypanosoma brucei in blood or CSF | Positive PCR for HSV DNA in CSF |
MRI may show diffuse meningoencephalitis without temporal lobe predominance | MRI showing temporal lobe hyperintensities |
African Sleeping Sickness (Trypanosoma brucei) versus Tuberculous Meningitis
African Sleeping Sickness (Trypanosoma brucei) | Tuberculous Meningitis |
|---|---|
Exposure to tsetse fly endemic regions in Africa | History of exposure to tuberculosis or residence in endemic area |
CSF pleocytosis with trypomastigotes and normal to mildly decreased glucose | CSF with lymphocytic pleocytosis, very low glucose, and elevated protein; acid-fast bacilli on smear or culture |
Detection of Trypanosoma brucei in CSF by microscopy or PCR | Positive CSF PCR or culture for Mycobacterium tuberculosis |
African Sleeping Sickness (Trypanosoma brucei) versus Leishmaniasis (Visceral)
African Sleeping Sickness (Trypanosoma brucei) | Leishmaniasis (Visceral) |
|---|---|
Exposure to tsetse fly in sub-Saharan Africa | Exposure to sandfly bites in endemic regions such as South Asia or South America |
Trypomastigotes of Trypanosoma brucei in blood or CSF | Amastigotes of Leishmania species in bone marrow or spleen aspirate |
Early systemic symptoms with CNS involvement causing sleep disturbances | Chronic fever, hepatosplenomegaly, and pancytopenia without CNS involvement |